Abstract: Methods and compositions relating to leaf extracts obtained from Morinda citrifolia leaves. Methods and compositions relating to a leaf serum created from combining leaf extract and fruit juice from the Morinda citrifolia L. plant. Methods and compositions relating to leaf extract compositions comprising one or more of the leaf extracts and leaf serums.

Abstract: A method and composition for inhibiting certain enzymes, where such inhibition results in various health benefits is provided. More particularly, a method and composition using one or more of the following: Noni Leaf Extract; Noni Leaf Juice; and/or Roast Leaf to inhibit the following: HMG-CoA Reductase; Phosphodiesterases (3 and 4) PDE3 and PDE4; 5-Lipoxygenase (LOX) and 15-LOX; Xanthine Oxidase (XO); Gamma Amino Butyric Acid (GABA) and the growth of the second most common human skin cancer cell line, is provided. Moreover, the foregoing enzymatic inhibitions result in: alleviating pain and inflammation; treating prostate cancers; lowering cholesterol levels; counteracting Diabetes Type II; maintaining the highest possible integrity of cellular interactions in the brain resulting in an undisturbed neural function, (i.e.

Abstract: The present invention provides a formulation which may be utilized in agricultural practice that is eco-friendly and effective as plant growth promotion agent, soil improvement agent, bactericide and insecticide agent, disease and harmful insect prevention agent, and is suitable for organic farming. The formulation of the present invention is comprised of a Morinda citrifolia product or extract. The formulation of the present invention may be applied to fruit vegetables, leafy vegetables, root vegetables, grains as well as flowers and shrubs, increasing the amount of yield and extending freshness period after harvest. Further, the present invention relates to antifungal and antibacterial activity of processed Morinda citrifolia products, as well as from various fractions of extracts from these processed products and the Morinda citrifolia L. plant, and related methods to determine mean inhibitory concentrations.

Abstract: The present invention relates to methods and formulations directed to the management of various Matrix Metalloproteinases enzymes comprising the administration of processed Morinda citrifolia based formulations.

Abstract: The present invention is directed to methods and formulations for inhibiting Lipoxygenase enzymes that function to biosynthesize or metabolize arachidonic acid into its intermediate Leukotriene constituents, as well as a method and formulation for treating and preventing diseases, including inflammatory diseases, and the symptoms associated with such diseases. The present invention methods and formulations effectively function as such through the introduction into the body (e.g. ingesting) a safe, pre-determined dosage of a naturaceutical composition formulated with or comprising one or more processed Morinda citrifolia products for a safe, pre-determined duration, wherein the processed Morinda citrifolia product may comprise one or more isolated active ingredients.

Abstract: The present invention relates to nutraceutical formulations and methods for use of fetid oil derived from Morinda citrifolia seeds. Research supporting this invention indicates that processed Morinda citrifolia seed products may be used for weight management and health promotion. The present invention is supported by research findings related to the nutritional benefits of fetid oil extracted from the seeds contained within Morinda citrifolia fruit. This oil has been found to include high concentrations of linoleic acid, which is known to increase metabolic rate, help prevent cancer, protect the liver, and help prevent the build up of artery plaque. These observations are consistent with the concept that noni, can positively affect the regulation of excess body weight and promote overall good health.

Abstract: The invention relates to formulations and methods for preventing and/or treating substance abuse, addiction, withdrawal symptoms, and anticipation associated with substance abuse. In particular the invention relates to formulations comprising at least one processed Morinda citrifolia L. product, and methods comprising the administration of at least one processed Morinda citrifolia L product to prevent and/or treat substance abuse, addiction, withdrawal symptoms, and anticipation associated with substance abuse in living organisms. Embodiments of the invention further comprise Morinda citrifolia based nutraceuticals and administration thereof to affect regulation of dopamine levels, inhibition of opioid receptors, inhibition of mu opioid receptors, inhibition of kappa opioid receptors, inhibition of delta opioid receptors, acting as NMDA antagonist, inhibition of sensitization of NMDA receptors, and/or acting as opiate antagonists.

Abstract: The present invention advances prior art animal food products by providing an animal food product formulated with Garicinia mangostana L., or Mangosteen fruit, from the Mangosteen plant. The addition of Mangosteen to the animal food product of the present invention serves to provide significant health advantages not found in prior art animal food products.

Abstract: The present invention relates to methods and compositions for reactivating Acetylcholinesterase in living organisms using contents from the Morinda citrifolia L. plant. More particularly, the present invention relates to methods and compositions involving the reactivation of Acetylcholinesterase using fruit juice obtained from the Morinda citrifolia L. plant.

Abstract: The present invention relates to methods and formulations directed to the management of Cathepsin G, Cathepsin S, Cathepsin B, Cathepsin L, Butyryl Cholinesterase, Peptidase HIV-1, and NF-kB enzymes comprising the administration of processed Morinda citrifolia based formulations.

Abstract: The present invention is directed to methods of inhibiting Aromatase or Aromatase enzymes that function to convert androgens to estrogens, inhibiting receptors from binding with estrogen, and reducing and/or regulating estrogen production, as well as reducing the amount of estrogen produced within the body and regulating such production. The present invention methods and compositions effectively function to treat estrogen-dependent cancers, and particularly inhibit, destroy, and reverse the effects of of estrogen-dependent cancerous tumors through the introduction into the body (e.g. ingesting) a safe, pre-determined dosage of a naturaceutical composition formulated with or comprising one or more processed Morinda citrifolia products for a safe, pre-determined duration.

Abstract: The present invention relates to weight management utilizing processed Morinda citrifolia products. Research supporting this invention indicates that processed Morinda citrifolia products may be used in weight management. The present invention is supported by research findings that suggest that oral administration of Morinda citrifolia can increase metabolic rate. An increased metabolic rate causes an individual to burn an increased amount of body fat. These observations are consistent with the concept that noni, can positively affect the regulation of excess body weight.

Abstract: The present invention relates to methods and compositions for inhibiting Histone Deacetylase (“HDAC”) and/or Tumor Necrosis Factor Converting Enzyme (“TACE”) in living organisms. More particularly, the present invention relates to methods and compositions involving the inhibition of HDAC and/or TACE using processed Morinda citrifolia L. plant products.

Abstract: Methods and formulations that utilize components of the Indian Mulberry plant, scientifically known as Morinda citrifola L., to treat one or more oral and dental disorders, including periodontal diseases such as gingivitis and periodontitis, tooth decay, halitosis, and other mouth disorders and irritations.

Abstract: The present invention relates to antifungal and antibacterial activity of processed Morinda citrifolia products, as well as from various fractions of extracts from these processed products and the Morinda citrifolia L. plant, and related methods to determine mean inhibitory concentrations. In particular, the present invention relates to ethanol, methanol and ethyl acetate extracts from Morinda citrifolia L. and their inhibitory activities on common fungi and bacteria and the identification of mean inhibitory concentrations.

Abstract: The present invention advances prior art animal food products by providing an animal food product formulated with Garicinia mangostana L., or Mangosteen fruit, from the Mangosteen plant. The addition of Mangosteen to the animal food product of the present invention serves to provide significant health advantages not found in prior art animal food products.

Abstract: The present invention relates to methods and compositions which act as nicotinic acetylcholine receptor antagonist in living organisms. More particularly, the present invention relates to methods and compositions which act as nicotinic acetylcholine receptor antagonist using processed Morinda citrifolia L. plant products.

Abstract: The present invention is directed to methods and formulations for inhibiting Lipoxygenase or Lipoxygenase enzymes that function to biosynthesize or metabolize arachidonic acid into its intermediate Leukotriene constituents, as well as a method and formulation for treating and preventing inflammatory diseases and the symptoms associated with such diseases. The present invention methods and formulations effectively function as such through the introduction into the body (e.g. ingesting) a safe, pre-determined dosage of a naturaceutical composition formulated with or comprising one or more processed Morinda citrifolia products for a safe, pre-determined duration, wherein the processed Morinda citrifolia product may comprise one or more isolated active ingredients.

Abstract: The invention relates to formulations and methods for preventing and/or treating substance abuse, addiction, withdrawal symptoms, and anticipation associated with substance abuse. In particular the invention relates to formulations comprising at least one processed Morinda citrifolia L. product, and methods comprising the administration of at least one processed Morinda citrifolia L product to prevent and/or treat substance abuse, addiction, withdrawal symptoms, and anticipation associated with substance abuse in living organisms. Embodiments of the invention further comprise Morinda citrifolia based nutraceuticals and administration thereof to affect regulation of dopamine levels, inhibition of opioid receptors, inhibition of mu opioid receptors, inhibition of kappa opioid receptors, inhibition of delta opioid receptors, acting as NMDA antagonist, inhibition of sensitization of NMDA receptors, and/or acting as opiate antagonists.

Abstract: The present invention relates to the inhibition of xanthine oxidase. In particular, the present invention relates to systems and methods for utilizing Morinda citrifolia L. based compositions and methods to inhibit xanthine oxidase activity.